Cover Image

Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience

Dalbavancin is a long-acting lipoglycopeptide that is registered for the treatment of acute bacterial skin and skin structure infections, and it is also increasingly used for infections that require prolonged antibiotic treatment. Here, we present the results from the first 2 years of a service set...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dario Cattaneo (Author), Marta Fusi (Author), Marta Colaneri (Author), Chiara Fusetti (Author), Camilla Genovese (Author), Riccardo Giorgi (Author), Maddalena Matone (Author), Stefania Merli (Author), Francesco Petri (Author), Andrea Gori (Author)
Format:	Book
Published:	MDPI AG, 2023-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
by: Altea Gallerani, et al.
Published: (2023)

Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Dalbavancin
by: Ute Chiriac, et al.
Published: (2022)

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
by: Lucia Brescini, et al.
Published: (2021)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
by: Dario Cattaneo, et al.
Published: (2020)

Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing
by: Désirée Caselli, et al.
Published: (2024)

Dalbavancin in Bone and Joint Infections: A Systematic Review
by: Sofia Lovatti, et al.
Published: (2023)

Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring
by: Pier Giorgio Cojutti, et al.
Published: (2022)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
by: Elisa Molinelli, et al.
Published: (2022)

Dalbavancin in the treatment of skin and soft tissues infection
by: Ana Candela Fajardo, et al.
Published: (2017)

Evaluating the Use of Dalbavancin for Off-Label Indications
by: Katherine Taylor, et al.
Published: (2022)

Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study
by: Petros Ioannou, et al.
Published: (2023)

In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
by: Mar Sánchez-Somolinos, et al.
Published: (2023)

In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR) <i>Staphylococcus aureus</i> Isolates
by: Dafne Bongiorno, et al.
Published: (2020)

Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections
by: Rossella Barone, et al.
Published: (2023)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
by: Luis Buzón-Martín, et al.
Published: (2021)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
by: Leama Ajaka, et al.
Published: (2020)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
by: Simonetti O, et al.
Published: (2021)

Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis
by: Christoph T. Baltin, et al.
Published: (2023)

Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges
by: Stefania Cheli, et al.
Published: (2023)

Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections
by: Giustino Parruti, et al.
Published: (2024)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
by: Giacomo Stroffolini, et al.
Published: (2022)

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections
by: Dimitra Dimopoulou, et al.
Published: (2023)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
by: Andrés Ruiz-Sancho, et al.
Published: (2023)

Dalbavancin in the treatment of complicated skin and soft-tissue infections: a review
by: Jason W Bennett, et al.
Published: (2008)

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
by: Gatti M, et al.
Published: (2021)

Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on an <i>In Vitro</i> Study
by: Mar Sánchez-Somolinos, et al.
Published: (2022)

Real-life lack of evidence of viable SARS-CoV-2 transmission via inanimate surfaces: The SURFACE study
by: José Camilla Sammartino, et al.
Published: (2023)

Clinical outcomes following dalbavancin administration in patients with barriers to outpatient parenteral antimicrobial therapy
by: Jessica J. Tuan, et al.
Published: (2022)

Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI)
by: Leuthner KD, et al.
Published: (2016)

Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series
by: Connor Evins, et al.
Published: (2022)

Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study
by: Thamer A. Almangour, et al.
Published: (2020)

Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience
by: Sara Maria Scarano, et al.
Published: (2024)

Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and <i>Enterococcus faecium</i>
by: Robert E. Weber, et al.
Published: (2021)

A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice
by: Frank Hanses, et al.
Published: (2022)

New developments in the treatment of acute bacterial skin and skin structure infections: considerations for the effective use of dalbavancin
by: Juul JJ, et al.
Published: (2016)

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
by: Carmen Hidalgo-Tenorio, et al.
Published: (2019)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
by: Pedro Luis Gonzalez, et al.
Published: (2018)

Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections
by: Ute Chiriac, et al.
Published: (2024)

Prescriptive appropriateness of dalbavancin in acute bacterial skin and skin structure infections in adults: an integrated approach between clinical profile, patient- and health system-related factors and focus on environmental impact
by: Francesco Di Gennaro
Published: (2024)

Systems compared: Capillary glucose self-monitoring and Flash glucose monitoring system. Cross-sectional study
by: Francesco Saverio Auricchio, et al.
Published: (2023)